Arthritis Research & Therapy, 2022 Objectives We compared the treatment effectiveness between guselkumab and adalimumab in patients with pustulotic arthro-osteitis (PAO). In addition, we performed peripheral blood immunophenotyping to elucidate the immunological background and analyzed ...
Masanobu Ueno +7 more
doaj +1 more source
Secukinumab in the treatment of psoriasis: patient selection and perspectives. [PDF]
, 2018 Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Beck, Kristen M +2 more
core +1 more source
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis [PDF]
, 2007 International audienceThis paper presents numerical crack propagations in case of explicit dynamics, and applied to eXtended Finite Element Method. The interest of this method is non remeshing. Hence the crack propagates through the constant mesh.
Campa, Molly +3 more
core +1 more source
Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation [PDF]
, 2023 Background Guselkumab is a drug used to treat moderate to severe plaque psoriasis. However, real-life clinical data on its of-label use are limited, especially regarding the optimal drug dosage regimen for diferent patient profles.
Alonso Pacheco, Maria Luisa +7 more
core +1 more source
Arthritis Research & Therapy, 2023 Background Guselkumab is a selective interleukin (IL)-23 inhibitor targeting the IL-23p19 subunit. In the phase 3b COSMOS trial, guselkumab demonstrated efficacy in treating participants with active psoriatic arthritis (PsA) and inadequate response (IR ...
Georg Schett +9 more
doaj +1 more source
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study [PDF]
, 2023 Background & aims: The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) with prior inadequate response and/
Allegretti, Jessica R +17 more
core +1 more source
Adverse reactions of biological therapies in patients with psoriasis [PDF]
, 2017 Psoriasis is a chronic, immune-mediated disorder characterized by well demarcated, erythematous plaques covered by thick, silvery-white scales, most often located on the knees, elbows, sacral area and scalp.
Georgescu, Simona R. +5 more
core +4 more sources
F1000Research, 2022 Background: Psoriasis is a chronic inflammatory disease which can impact quality of life. In the past decade multiple biologic treatments have been released with encouraging results. Guselkumab is a monoclonal antibody targeting IL-23p19.
Fiorella Vasquez Chinchay +5 more
doaj +1 more source
Clinical consequences of antibody formation, serum concentrations, and HLA-Cw6 status in psoriasis patients on Ustekinumab [PDF]
, 2019 Background: Ustekinumab for the treatment of psoriasis is currently administered in a standard dosing regimen. However, some patients tend to benefit from alternative dosing regimens, a step toward personalized medicine.
Busard, Celine, I +9 more
core +1 more source
NCR+ ILC3 maintain larger STAT4 reservoir via T-BET to regulate type 1 features upon IL-23 stimulation in mice [PDF]
, 2018 Innate lymphoid cells (ILCs) producing IL-22 and/or IL-17, designated as ILC3, comprise a heterogeneous subset of cells involved in regulation of gut barrier homeostasis and inflammation.
Kanno, Yuka +7 more
core +1 more source